Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.41 USD
-0.28 (-2.21%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $12.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 141 - 145 ( 145 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:EPS; Second-Generation Cloudbreak Strategy Announced, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE: 2015 Wedbush PacGrow Healthcare Conference Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CD101 Enters the Clinic, Quick Data Readout Expected, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:EPS; CD101 Granted Qualified Infectious Disease Product (QIDP) With Fast Track Status
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $22 Price Target: Better Living through New Antifungals
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D